rethinkPeptides Search
Menu
Study breakdown

Plant-Derived Peptide Ara-27 Penetrates Human Cells 8-22x Better Than Conventional CPPs

In VitroModerate evidence
The takeaway

A new cell-penetrating peptide derived from Arabidopsis achieved over 99% cell entry at just 2 μM, dramatically outperforming standard CPPs like Tat-PTD and MTS.

>99% vs <10% penetration

Ara-27 achieved near-complete cell entry at 2 μM while standard CPPs Tat-PTD and MTS showed minimal uptake

What the researchers found

Ara-27 achieved >99% cell-penetrating efficiency at 2 μM in human cells compared to <10% for Tat-PTD and MTS, with 8-22x higher intracellular fluorescence intensity.

Why it matters

Getting drugs and molecules inside cells is a major challenge in medicine. A CPP that works at low concentrations with near-complete efficiency could transform drug delivery for gene therapies, siRNA, and small molecules.

The numbers in context

>99% penetration at 2 uM (Ara-27) vs <10% (TAT, MTS); 8-22x fluorescence intensity; internalized at 0.2 uM; no cytotoxicity

How the study worked

In-vitro comparison study using flow cytometry and confocal microscopy to measure FITC-labeled peptide uptake in human dermal fibroblasts and dental pulp stem cells.

Who was studied

Human dermal fibroblasts (HDF) and human dental pulp stem cells (hDPSC) treated with Ara-27, TAT-PTD, and MTS

What this study cannot tell us

In-vitro study only with two human cell types; no in-vivo testing; cargo delivery efficiency not tested; mechanism of enhanced uptake not fully characterized.

How to read the evidence

Strong in-vitro evidence with quantitative comparisons across two cell types, but lacks in-vivo validation and cargo delivery testing.

When this study was published

Published in 2020; Ara-27 is a relatively new CPP and follow-up in-vivo studies would strengthen its therapeutic potential.

The bigger picture

This represents a significant advance in peptide-based drug delivery technology, potentially enabling more efficient intracellular delivery of therapeutics that currently cannot cross cell membranes effectively.

Questions still open

  • Does Ara-27 maintain its superior penetration when carrying therapeutic cargo like siRNA or drugs?
  • How does Ara-27 perform in vivo — does it show tissue-specific uptake or broad biodistribution?
  • What is the mechanism behind Ara-27 dramatically superior cell entry compared to Tat-PTD?

Common questions

What makes Ara-27 better than other cell-penetrating peptides?
Ara-27 achieved over 99% cell entry at just 2 μM concentration, while standard CPPs like Tat-PTD showed less than 10% — an 8-22x improvement in delivery efficiency.
Where does Ara-27 come from?
Ara-27 is derived from Arabidopsis, a model plant species. It was synthetically produced and tested in human cells for drug delivery potential.

Read the original research

Newly synthesized peptide, Ara-27, exhibits significant improvement in cell-penetrating ability compared to conventional peptides.

Biotechnology progress, 36(5), e3014

Citation

Min, Sol; Kim, Kichul; Ku, Seockmo; Park, Jeong-Yoon; Seo, Jeongmin; Roh, Sangho. (2020). Newly synthesized peptide, Ara-27, exhibits significant improvement in cell-penetrating ability compared to conventional peptides.. Biotechnology progress, 36(5), e3014. https://doi.org/10.1002/btpr.3014